B-Raf(V600E) and Thrombospondin-1 promote thyroid cancer progression

Carmelo Nucera, A Porrello, Za Antonello, M Mekel, M Nehs, T Giordano, D Gerald, L Benjamin, Carmen Priolo, E Puxeddu, S Finn, B Jarzab, R Hodin, Alfredo Pontecorvi, V Nose, J Lawler, S. Parangi

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Although B-Raf(V600E) is the most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor aggressiveness is not fully understood. Using gene set enrichment analysis and in vitro and in vivo functional studies, we identified and validated a B-Raf(V600E) gene set signature associated with tumor progression in PTCs. An independent cohort of B-Raf(V600E)-positive PTCs showed significantly higher expression levels of many extracellular matrix genes compared with controls. We performed extensive in vitro and in vivo validations on thrombospondin-1 (TSP-1), because it has been previously shown to be important in the regulation of tumor angiogenesis and metastasis and is present in abundance in tumor stroma. Knockdown of B-Raf(V600E) resulted in TSP-1 down-regulation and a reduction of adhesion and migration/invasion of human thyroid cancer cells. Knockdown of TSP-1 resulted in a similar phenotype. B-Raf(V600E) cells in which either B-Raf(V600E) or TSP-1 were knocked down were implanted orthotopically into the thyroids of immunocompromised mice, resulting in significant reduction in tumor size and fewer pulmonary metastases from the primary carcinoma as compared with the control cells. Treatment of orthotopic thyroid tumors, initiated 1 week after tumor cell implantation with PLX4720, an orally available selective inhibitor of B-Raf(V600E), caused a significant tumor growth delay and decreased distant metastases, without evidence of toxicity. In conclusion, B-Raf(V600E) plays an important role in PTC progression through genes (i.e., TSP-1) important in tumor invasion and metastasis. Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720
Lingua originaleEnglish
pagine (da-a)1178-1179
Numero di pagine2
RivistaProceedings of the National Academy of Sciences of the United States of America
Stato di pubblicazionePubblicato - 2010


  • B-RAF


Entra nei temi di ricerca di 'B-Raf(V600E) and Thrombospondin-1 promote thyroid cancer progression'. Insieme formano una fingerprint unica.

Cita questo